Mesa Laboratories (MLAB) AI Stock Analysis

• Market Cap: $434.49M
• Dividend Yield: 0.81%
• Average Volume (3M): 140.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: 7.39%
• EPS Growth: 99.34%
• Country: US
• Employees: 736
• Sector: Technology
• Sector Strength: 88
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 2.75
• Shares Outstanding: 5,522,299
• 10 Day Avg. Volume: 220,631
• 30 Day Avg. Volume: 140,549
• PEG Ratio: 3.29
• Price to Book (P/B): 4.03
• Price to Sales (P/S): 2.67
• P/FCF Ratio: 15.23
• Enterprise Value/Market Cap: 1.22
• Enterprise Value/Revenue: 2.16
• Enterprise Value/Gross Profit: 3.58
• Enterprise Value/Ebitda: 12.46
• 1Y Price Target: $115.00
• Price Target Upside: 46.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 7.32
• Revenue Forecast (FY): $248.97M

• Rating: 51 Neutral
• Price Target: $78.00 ▼(-0.86% Downside)

Mesa Laboratories' overall stock score reflects a mixed financial performance with strong cash flow but significant profitability challenges and high leverage. Technical analysis suggests a neutral to slightly positive trend, while valuation metrics are unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

The 5.0% organic revenue growth indicates solid market execution and stability, suggesting Mesa Laboratories is effectively expanding its market presence.

Cash Flow Generation

Strong free cash flow growth demonstrates Mesa's ability to generate cash efficiently, providing financial flexibility and supporting long-term investments.

Market Position

Stable market presence in key regions like Europe and North America enhances Mesa's competitive position, supporting sustained revenue growth and market share.

Negative Factors

High Leverage

Significant leverage could pose financial risks, limiting Mesa's ability to invest in growth opportunities and increasing vulnerability to economic downturns.

Profitability Challenges

Ongoing profitability issues, as indicated by negative net margins, suggest Mesa may struggle to convert revenue growth into sustainable profits.

Negative Net Income

Consistent negative net income highlights operational inefficiencies and challenges in achieving profitability, which could hinder long-term financial health.

Mesa Laboratories Business Overview & Revenue Model

Company Description

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

How the Company Makes Money

Mesa Laboratories generates revenue through the sale of its diverse range of monitoring and testing products. Key revenue streams include the sale of hardware devices, such as temperature and humidity sensors, along with software solutions that facilitate data collection and analysis. Additionally, the company offers ongoing maintenance and calibration services, which provide a recurring revenue stream. Significant partnerships with regulatory agencies and industry leaders enhance its market presence and contribute to its earnings by ensuring that its products meet the stringent quality standards required in life sciences applications.

Mesa Laboratories Financial Statement Overview

Summary

Mesa Laboratories presents a mixed financial picture. While there is some revenue growth and strong cash flow generation, the company faces challenges with profitability and high leverage. The negative net income and high debt-to-equity ratio are key areas of concern.

Income Statement

Mesa Laboratories shows a mixed performance in its income statement. The TTM data indicates a slight revenue growth of 1.2%, but the company is struggling with profitability, as evidenced by a negative net profit margin of -0.26%. The gross profit margin remains healthy at 60.29%, but the EBIT and EBITDA margins are relatively low at 8.11% and 18.43%, respectively. The negative net income is a concern, indicating challenges in achieving profitability.

Balance Sheet

The balance sheet reflects a moderate financial position. The debt-to-equity ratio is high at 1.07, suggesting significant leverage, which could pose risks if not managed properly. The return on equity is negative, indicating inefficiencies in generating returns from shareholders' equity. However, the equity ratio is reasonable, showing that a fair portion of assets is financed by equity.

Cash Flow

Cash flow analysis reveals some positive trends. The TTM free cash flow growth rate is strong at 10.84%, and the operating cash flow to net income ratio is healthy at 0.26, indicating good cash generation relative to net income. The free cash flow to net income ratio is also robust at 0.88, suggesting that the company is generating sufficient free cash flow relative to its net income, despite the latter being negative.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	245.25M	240.98M	216.19M	219.08M	184.34M	133.94M
Gross Profit	147.99M	150.87M	133.25M	133.69M	109.09M	87.01M
EBITDA	42.48M	42.35M	-238.38M	37.52M	32.53M	27.99M
Net Income	-1.57M	-1.97M	-254.25M	930.00K	1.87M	3.27M
Balance Sheet
Total Assets	430.35M	433.35M	446.80M	661.83M	707.37M	601.48M
Cash, Cash Equivalents and Short-Term Investments	20.42M	27.32M	28.21M	32.91M	49.35M	263.87M
Total Debt	110.69M	181.47M	231.30M	186.14M	221.13M	146.70M
Total Liabilities	251.88M	273.52M	301.40M	268.35M	313.57M	195.25M
Stockholders Equity	178.47M	159.83M	145.39M	393.48M	393.80M	406.23M
Cash Flow
Free Cash Flow	37.30M	42.31M	41.57M	23.44M	34.79M	35.08M
Operating Cash Flow	41.22M	46.81M	44.13M	27.98M	39.22M	37.07M
Investing Cash Flow	-3.92M	-4.50M	-81.31M	-9.49M	-305.23M	-1.99M
Financing Cash Flow	-43.10M	-44.51M	32.84M	-33.33M	52.58M	146.23M

Mesa Laboratories Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 78.68
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLAB, the sentiment is Positive. The current price of 78.68 is above the 20-day moving average (MA) of 75.73, above the 50-day MA of 73.48, and below the 200-day MA of 93.24, indicating a neutral trend. The MACD of 1.26 indicates Negative momentum. The RSI at 56.56 is Neutral, neither overbought nor oversold. The STOCH value of 76.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MLAB.

Mesa Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LYTS	66 Neutral	$559.05M	22.37	11.03%	1.11%	22.35%	2.59%
DAKT	64 Neutral	$892.47M	4,179.55	4.36%	―	-7.67%	7.66%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
RELL	61 Neutral	$147.31M	477.31	0.11%	2.33%	6.17%	―
VPG	60 Neutral	$457.60M	57.97	2.37%	―	-7.46%	-39.98%
MLAB	51 Neutral	$434.49M	―	-0.92%	0.81%	7.39%	99.34%
LPTH	51 Neutral	$325.71M	―	-37.93%	―	36.85%	-77.93%

Mesa Laboratories Corporate Events

Mesa Laboratories Reports Revenue Growth Amid Challenges

Mesa Laboratories, Inc., a global leader in life science tools and quality control solutions, operates across four divisions: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics. The company recently reported its second-quarter financial results, highlighting a 5.0% increase in revenues and a 34.7% rise in operating income, despite a 27.8% decrease in net income. The growth was driven by strong performance in the Biopharmaceutical Development and Calibration Solutions divisions, while the Clinical Genomics division faced challenges in China. Mesa Laboratories also reported a 6.1% increase in adjusted operating income, excluding unusual items, and a significant reduction in annualized costs by $3.2 million. The company plans to reinvest some of these savings into its Sterilization and Disinfection Control division to support long-term growth. Looking ahead, Mesa Laboratories remains optimistic about its growth prospects, expecting sequential revenue increases in the upcoming quarter, supported by strategic initiatives and cost-saving measures.

Mesa Laboratories Holds Annual Shareholder Meeting

On August 22, 2025, Mesa Laboratories held its annual meeting of shareholders where 5,203,377 shares were represented. During the meeting, the election of directors was confirmed, with John J. Sullivan, Gary M. Owens, Jenny S. Alltoft, Shannon M. Hall, Shiraz S. Ladiwala, R. Tony Tripeny, and Mark C. Capone elected to the board for a one-year term. The board also appointed members to its committees. Additionally, the shareholders ratified the selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. The compensation of the company’s named executive officers was approved on a non-binding basis, and an amendment to the 2021 Equity Incentive Plan was also approved.

The most recent analyst rating on (MLAB) stock is a Hold with a $69.00 price target. To see the full list of analyst forecasts on Mesa Laboratories stock, see the MLAB Stock Forecast page.